Key result
Health authorities across Europe have implemented extensive pre-, peri-, and post-launch activities, including risk-sharing and prescribing restrictions, to manage the introduction of dabigatran.
Comprehensive models for introducing new drugs, centering on pre-, peri-, and post-launch activities, are essential to optimize prescribing and manage safety and budget concerns, as demonstrated by the introduction of dabigatran.
No takes yet. Share an insight, caveat, or question.
Alerts to dabigatran safety issues in elderly AF; leaves open optimal use amid funding conflicts.
Malmström et al. (2013) conducted a review in Atrial fibrillation. Dabigatran was evaluated. Health authorities across Europe have implemented extensive pre-, peri-, and post-launch activities, including risk-sharing and prescribing restrictions, to manage the introduction of dabigatran.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: